Followers | 259 |
Posts | 3732 |
Boards Moderated | 0 |
Alias Born | 04/26/2013 |
Sunday, September 27, 2015 8:54:16 AM
Wow! All that dilution this year (not from conversion, which also jacked the shares outstanding, but from NEW ISSUANCE - see below), and they didn't have enough money to complete the lab? They had a "grand opening" party four months ago! They said that they were leasing the equipment. Why would they need another $200K? My guess is because they have to pay salaries for the employees who just sit there with nothing to do, unfortunately.
The 10-Q points to $1.57mm net raised so far in 2015 through 6/30:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10874438
*$900K net from converts
*$580K from issuance of Preferred A
*$90K from equity sales and management contributions
I guess that wasn't enough! After the quarter, also:
This is the toxic debt that the company will be choking on in the coming months.
I can't get excited about this deal, but, yes, it could have been worse. They could have issued yet more toxic debt, and instead they sold the first sales and income on their prize jewel. Investors have been looking forward to the lab opening, as the cash could have been used to retire the pending convertible note expirations. The fact is that it is now MORE LIKELY that there will be dilution from these previously issued notes.
PZOO had no money when this marijuana lab venture started and no real business. As of today, 18 months after telling the world it was a pot stock, it has not made a single dollar from the labs (because none are yet open). It has raised a bunch of capital but siphoned a great deal of it to its outside partners already (with some used for construction). They should have structured the deal so that Harris Lee and MA Associates (M and A are already gone!) didn't get paid until the license started producing revenue. Once again, the insiders score, while the shareholders bend over.
The bottom-line is that shareholders have been and will continue to be diluted here. The capital structure stinks, and it is obvious that there won't be enough cash to pay the convertible notes, despite the assurances from the CEO. This $200K "non-dilutive" debt looks like it jumps in front of shareholders (no terms have been disclosed, so this is based on the press release), compounding the challenges to pay off the toxic convertible notes. The company has foolishly borrowed from multiple lenders, so the first to convert is going to smack this one silly to get out. Toxic. Death. Spiral.
If you don't like my posts, don't read them. If you think only those who agree with you should post, then start your own message board. My conclusions are my opinion only, based on what I believe to be true. I have no crystal ball.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM